LUCENTIS 0.5 mg Prefilled Syringe

The efficacy and safety of LUCENTIS 0.5 mg studied in 7 pivotal trials, available in a prefilled syringe.

† The following randomized, double-masked pivotal trials were conducted for the 3 LUCENTIS indications: wAMD: MARINA—Phase III, multicenter, 2-year, sham injection–controlled study; primary end point at 1 year. ANCHOR—Phase III, multicenter, 2-year, active treatment–controlled study; primary end point at 1 year. PIER—Phase IIIb, 2-year, sham injection–controlled study; primary end point at 1 year. HARBOR—Phase III, multicenter, 2-year, active treatment–controlled dose-response study; primary end point at 1 year. RVO: BRAVO—Phase III, multicenter, 1-year, sham injection–controlled study; primary end point at 6 months. CRUISE—Phase III, multicenter, 1-year, sham injection–controlled study; primary end point at 6 months. mCNV: RADIANCE—Phase III, multicenter, 1-year, active-controlled study; key clinical outcomes at month 3.1-7,9

Download and print a Preparation and Administration Flashcard here:

Order LUCENTIS 0.5 mg Prefilled Syringe before your patient’s next scheduled appointment

LUCENTIS 0.5 mg Prefilled Syringe is available through LUCENTIS Direct and authorized specialty distributors.